---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105159"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:17:33.002795+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025

## Summary
- Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.
- Cash, equivalents and marketable securities $205.1M; cash runway into early 2027.
- R&D and G&A expenses $48.7M (down 35% YoY); restructuring costs $18.4M from luvelta deprioritization.
- STRO-004 FIH trial on track for H2 2025; STRO-006 clinical in 2026; dual-payload ADC IND filing in 2027.
- Astellas milestone triggered $7.5M payment; Ipsen terminates STRO-003; Greg Chow appointed CFO.

## SEC filing metadata
- accession: 0000950170-25-105159
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/0000950170-25-105159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/stro-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105159
- JSON: https://secwatch.observer/filing/0000950170-25-105159.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.